Here is the value of Forward Pharma’s claim
According to a memo from investment bank Jefferies, Danish biotech Forward Pharma could stand to earn billions in royalties from Biogen Idec if it wins a patent case against its US-based rival.
BY STEFAN SINGH KAILAY
50/50. According to investment bank Jefferies those are the odds of Forward Pharma winning its patent dispute with Biogen Idec, in which it claims that the US-based drug giant has violated one of its patents.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bumpy start to Forward Pharma’s IPO
For abonnenter
Forward Pharma’s IP rights impress
For abonnenter
Danish company to wage war on drug giant
For abonnenter
